Alcobra Ltd (ADHD) was Resumed by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 21, 2016.
Many Wall Street Analysts have commented on Alcobra Ltd. Cantor Fitzgerald Initiated Alcobra Ltd on Jun 7, 2016 to “Buy”, Price Target of the shares are set at $16.
Alcobra Ltd opened for trading at $4.25 and hit $4.4 on the upside on Monday, eventually ending the session at $4.3, with a gain of 1.18% or 0.05 points. The heightened volatility saw the trading volume jump to 64,512 shares. Company has a market cap of $119 M.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.